Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 669

1.

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M.

Lancet Haematol. 2017 May 15. pii: S2352-3026(17)30080-7. doi: 10.1016/S2352-3026(17)30080-7. [Epub ahead of print]

PMID:
28522110
2.

MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines.

Rohrbach TD, Jones RB, Hicks PH, Weaver AN, Cooper TS, Eustace NJ, Yang ES, Jarboe JS, Anderson JC, Willey CD.

Oncol Lett. 2017 Mar;13(3):1216-1222. doi: 10.3892/ol.2016.5550. Epub 2016 Dec 29.

3.

Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC.

Cell Host Microbe. 2017 Apr 12;21(4):494-506.e4. doi: 10.1016/j.chom.2017.03.008.

PMID:
28407485
4.

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.

Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, Specks U, Merkel PA, Jayne DR; RITAZAREM Investigators..

Trials. 2017 Mar 7;18(1):112. doi: 10.1186/s13063-017-1857-z.

5.
6.

IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.

Raposo RA, de Mulder Rougvie M, Paquin-Proulx D, Brailey PM, Cabido VD, Zdinak PM, Thomas AS, Huang SH, Beckerle GA, Jones RB, Nixon DF.

JCI Insight. 2017 Jan 12;2(1):e85811. doi: 10.1172/jci.insight.85811.

7.

Microwestern Arrays for Systems-Level Analysis of SH2 Domain-Containing Proteins.

Ciaccio MF, Jones RB.

Methods Mol Biol. 2017;1555:453-473. doi: 10.1007/978-1-4939-6762-9_27.

PMID:
28092050
8.

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE.

Bone Marrow Transplant. 2017 Apr;52(4):580-587. doi: 10.1038/bmt.2016.322. Epub 2016 Dec 19.

PMID:
27991894
9.

Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells.

Jones RB, Mueller S, Kumari S, Vrbanac V, Genel S, Tager AM, Allen TM, Walker BD, Irvine DJ.

Biomaterials. 2017 Feb;117:44-53. doi: 10.1016/j.biomaterials.2016.11.048. Epub 2016 Nov 25.

PMID:
27936416
10.

Early-Life Sugar Consumption Affects the Rat Microbiome Independently of Obesity.

Noble EE, Hsu TM, Jones RB, Fodor AA, Goran MI, Kanoski SE.

J Nutr. 2017 Jan;147(1):20-28. doi: 10.3945/jn.116.238816. Epub 2016 Nov 30.

PMID:
27903830
11.

Mini-Open Thoracolumbar Corpectomy: Perioperative Outcomes and Hospital Cost Analysis Compared with Open Corpectomy.

Sulaiman OAR, Garces J, Mathkour M, Scullen T, Jones RB, Arrington T, Bui CJ.

World Neurosurg. 2017 Mar;99:295-301. doi: 10.1016/j.wneu.2016.11.075. Epub 2016 Nov 25.

PMID:
27890745
12.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
13.

Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion.

Ranasinghe S, Lamothe PA, Soghoian DZ, Kazer SW, Cole MB, Shalek AK, Yosef N, Jones RB, Donaghey F, Nwonu C, Jani P, Clayton GM, Crawford F, White J, Montoya A, Power K, Allen TM, Streeck H, Kaufmann DE, Picker LJ, Kappler JW, Walker BD.

Immunity. 2016 Oct 18;45(4):917-930. doi: 10.1016/j.immuni.2016.09.015.

14.

Patient safety and institutional review boards in multi-institutional dose escalation or expansion trials.

Jones RB.

Lancet Oncol. 2016 Sep;17(9):1190-1. doi: 10.1016/S1470-2045(16)30320-5. Epub 2016 Aug 30. No abstract available.

PMID:
27599134
15.

Correction: Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes.

Willberg CB, Garrison KE, Jones RB, Meiklejohn DA, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF.

PLoS One. 2016 Jul 25;11(7):e0160293. doi: 10.1371/journal.pone.0160293. eCollection 2016.

16.

IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K.

Blood. 2016 Sep 8;128(10):1346-61. doi: 10.1182/blood-2016-01-695122. Epub 2016 Jul 20.

PMID:
27439912
17.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

PMID:
27377901
18.

T-cell therapies for HIV: Preclinical successes and current clinical strategies.

Patel S, Jones RB, Nixon DF, Bollard CM.

Cytotherapy. 2016 Aug;18(8):931-42. doi: 10.1016/j.jcyt.2016.04.007. Epub 2016 Jun 2. Review.

PMID:
27265874
19.

Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.

Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS.

Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20.

20.

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD.

PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.

Supplemental Content

Loading ...
Support Center